In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma

International Journal of Oncology

Volumn 27, Issue 4, 2005, Pages 1061-1070

  Förbs, Diana ^a   Thiel, Stefan ^a   Stella, Maria C ^b   Stürzebecher, Anne ^c   Schweinitz, Andrea ^c   Steinmetzer, Torsten ^c   Sturzebecher, Jörg ^d   Uhland, Kerstin ^a  

^a Curacyte AG   (Germany)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c Curacyte Chemistry GmbH   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cell scattering; Hepatocyte growth factor scatter factor; HGF SF; Inhibitors; Invasive growth; Matriptase; PPA; Serine protease; Urokinase

Indexed keywords

COLLAGEN; ENZYME INHIBITOR; LAMININ; MATRIGEL; MATRIPTASE; PEPTIDE HYDROLASE; PHENYLALANINE; PRO HEPATOCYTE GROWTH FACTOR; PRO-HEPATOCYTE GROWTH FACTOR; PROTEIN PRECURSOR; PROTEOGLYCAN; SCATTER FACTOR; SERINE PROTEINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER INVASION; CELL MEMBRANE; CELL PROLIFERATION; CHEMICAL MODEL; CHEMISTRY; COLON TUMOR; DISEASE COURSE; DOSE RESPONSE; DRUG COMBINATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; FEMALE; HUMAN; IC 50; IN VITRO STUDY; KINETICS; MALE; METABOLISM; METASTASIS; PROSTATE TUMOR; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; COLLAGEN; COLONIC NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LAMININ; MALE; MODELS, CHEMICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PEPTIDE HYDROLASES; PHENYLALANINE; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; PROTEIN STRUCTURE, TERTIARY; PROTEOGLYCANS; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 33644822482     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.4.1061     Document Type: Article

References (58)

1. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
2. Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-626, 1994.
3. Frisch SM and Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol 13: 555-562, 2001.
4. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
5. Trusolino L and Comoglio PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2: 289-300, 2002.
6. Bladt F, Riethmacher D, Isenmann S, Aguzzi A and Birchmeier C: Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768-771, 1995.
7. Schmidt C, Bladt F, Goedecke S, et al: Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373: 699-702, 1995.
8. Uehara Y, Minowa O, Mori C, et al:. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/ scatter factor. Nature 373: 702-705, 1995.
9. Matsumoto K and Nakamura T: NK4 (HGF-antagonist/ angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 94: 321-327, 2003.
10. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925,2003.
11. Hartmann G, Naldini L, Weidner KM, et al: A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc Natl Acad Sci USA 89: 11574-11578, 1992.
12. Kirchhofer D, Yao X, Peek M, et al: Structural and functional basis of the serine protease-like HGF beta -chain in Met binding and signaling. J Biol Chem 279: 39915-39924, 2004.
13. Lokker NA, Mark MR, Luis EA, et al: Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 11: 2503-2510, 1992.
14. Cao B, Su Y, Oskarsson M, et al: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 98: 7443-7448, 2001.
15. Abounader R, Lal B, Luddy C, et al: In vivo targeting of SF/HGF and c-met expression via UlsnRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 16: 108-110,2002.
16. Abounader R, Ranganathan S, Lal B, et al: Reversion of human glioblastoma malignancy by Ul small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 91: 1548-1556, 1999.
17. Lamszus K, Laterra J, Westphal M and Rosen EM: Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 17: 517-530, 1999.
18. Michieli P, Mazzone M, Basilico C, et al: Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6: 61-73, 2004.
19. Sidenius N and Blåsi F: The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22: 205-222, 2003.
20. Lee SL, Dickson RB and Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275: 36720-36725, 2000.
21. Suzuki M, Kobayashi H, Kanayama N, et al: Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 279: 14899-14908, 2004.
22. Kang JY, Dolled-Filhart M, Ocal IT, et al: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63: 1101-1105,2003.
23. List K, Haudenschild CC, Szabo R, et al: Matriptase/MT-SPl is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21: 3765-3779, 2002.
24. Benaud CM, Oberst M, Dickson RB and Lin CY: Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 19: 639-649, 2002.
25. Hoang CD, D'Cunha J, Kratzke MG, et al: Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125: 1843-1852, 2004.
26. Ihara S, Miyoshi E, Ko JH, et al:. Prometastatic effect of Nacetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J Biol Chem 277: 16960-16967, 2002.
27. Ihara S, Miyoshi E and Taniguchi N: Protease modified by sugar chain: beta 1-6 branching and matriptase. Tanpakushitsu Kakusan Koso 48: 980-983, 2003.
28. Santin AD, Cane S, Bellone S, et al: The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/ MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 98: 1898-1904,2003.
29. Santin AD, Zhan F, Bellone S, et al: Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112: 14-25, 2004.
30. Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH and O'Brien TJ: Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 22: 104-114,2001.
31. Schweinitz A, Steinmetzer T, Banke IJ, et al: Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 279: 33613-33622, 2004.
32. Sturzebecher J, Prasa D, Hauptmann J, Vieweg H and Wikstrom P: Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J Med Chem 40:3091-3099,1997.
33. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F and Comoglio PM: Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270: 603-611, 1995.
34. Elbashir SM, Harborth J, Weber K and Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26: 199-213, 2002.
35. Mars WM, Liu ML, Kitson RP, Goldfarb RH, Gabauer MK and Michalopoulos GK: Immediate early detection of urokinase receptor after partial hepatectomy and its implications for initiation of liver regeneration. Hepatology 21: 1695-1701, 1995.
36. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y and Kitamura N: Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem 268: 10024-10028, 1993.
37. Miyazawa K, Shimomura T and Kitamura N: Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J Biol Chem 271: 3615-3618, 1996.
38. Miyazawa K, Shimomura T, Naka D and Kitamura N: Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem 269: 8966-8970, 1994.
39. Shimomura T, Kondo J, Ochiai M, et al:. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem 268: 22927-22932, 1993.
40. Shimomura T, Miyazawa K, Komiyama Y, et al:. Activation of hepatocyte growth factor by two homologous proteases, bloodcoagulation factor Xlla and hepatocyte growth factor activator. Eur J Biochem 229: 257-261, 1995.
41. Peek M, Moran P, Mendoza N, Wickramasinghe D and Kirchhofer D: Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J Biol Chem 277: 47804-47809, 2002.
42. Dexter DL, Barbosa JA and Calabresi P: N,N-dimethylformamideinduced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res 39: 1020-1025, 1979.
43. Humphrey PA, Zhu X, Zarnegar R, et al: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147: 386-396, 1995.
44. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979.
45. Kataoka H, Hamasuna R, Itoh H, Kitamura N and Koono M: Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res 60: 6148-6159, 2000.
46. Takeuchi T, Shuman MA and Craik CS: Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad SciUSA96: 11054-11061, 1999.
47. Naldini L, Tamagnone L, Vigna E, et al:. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 11: 4825-4833, 1992.
48. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR and Craik CS: Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and singlechain urokinase-type plasminogen activator as substrates. J Biol Chem 275: 26333-26342, 2000.
49. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
50. Nielsen LS, Hansen JG, Skriver L, etal: Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 21: 6410-6415, 1982.
51. Wun TC, Ossowski L and Reich E: A proenzyme form of human urokinase. J Biol Chem 257: 7262-7268, 1982.
52. Ichinose A, Fujikawa K and Suyama T: The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261: 3486-3489, 1986.
53. Stack MS and Johnson DA: Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 269: 9416-9419, 1994.
54. Tjin EP, Derksen PW, Kataoka H, Spaargaren M and Pals ST: Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 104:2172-2175, 2004.
55. Mizuno K, Takehara T and Nakamura T: Proteolytic activation of a single-chain precursor of hepatocyte growth factor by extracellular serine-protease. Biochem Biophys Res Commun 189: 1631-1638, 1992.
56. Vesely D, Astl J, Lastuvka P, Matucha P, Sterzl I and Betka J: Serum levels of IGF-I, HGF, TGFbetal, bFGF and VEGF in thyroid gland tumors. Physiol Res 53: 83-89, 2004.
57. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME and Dickson RB: Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 53: 1409-1415, 1993.
58. Galkin AV, Mullen L, Fox WD, et al:. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 61: 228-235, 2004.